Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PROVENGE | Recruiting, Not yet recruiting, Available Studies
Previous Study | Return to List | Next Study

Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03329742
Recruitment Status : Recruiting
First Posted : November 6, 2017
Last Update Posted : September 12, 2019
Sponsor:
Collaborator:
Indiana University School of Medicine
Information provided by (Responsible Party):
Roberto Pili, Indiana University

Brief Summary:

This is a single-center, randomized, open-label study to assess the feasibility of a low-protein diet intervention in patients with metastatic castrate-resistant prostate cancer (CRPC) who are receiving treatment with sipuleucel-T. Subjects will be randomized (1:1 ratio) to either Arm 1 or Arm 2 (Fig. 1).

Arm 1: Subjects randomized to Arm 1 will be treated with sipuleucel-T infusion on Day 1, every two weeks for a total of three infusions. Subjects on this arm will receive a control diet containing 20% protein.

Arm 2: Subjects randomized to Arm 2 will be treated with sipuleucel-T infusion on Day 1, every two weeks for a total of three infusions. Subjects on this arm will receive a low-protein diet containing 10% protein.

Patients with metastatic, asymptomatic or minimally symptomatic CRPC that has progressed despite androgen deprivation therapy will be eligible for the study. After informed consent eligible patients will be scheduled to receive sipuleucel-T (three infusions two weeks apart) with normal-protein diet vs. low-protein diet. Each cycle will be every 14 days. Diet intervention will commence 1 week prior to the first apheresis (Day -7) and will continue until 10 days after the last infusion of sipuleucel-T (Day +42) (Fig. 2).


Condition or disease Intervention/treatment Phase
Prostate Cancer Recurrent Other: Low protein diet Other: Control protein diet Not Applicable

Detailed Description:

Primary Objective To assess the feasibility of low-protein diet intervention in patients with metastatic CRPC receiving immunotherapy with sipuleucel-T. Change in blood urea nitrogen (BUN) and urine urea nitrogen (UUN) from baseline to 6 weeks will be measured to assess adherence of following the diet intervention. The expected changes (mean, standard deviation) in BUN are 5.5 ± 2.6 mg/dL with 10% protein diet arm and 2.5 ± 2.6 mg/dL with 20% protein diet arm (please see section 12.5.7).

Secondary Objectives

  1. To assess whether low-protein diet intervention augments the immune response to sipuleucel-T in men with metastatic CRPC.
  2. To assess the safety and tolerability of the combination of sipuleucel-T and low-protein diet intervention.
  3. To obtain preliminary evidence of clinical efficacy of the combination of sipuleucel-T and low-protein diet compared to sipuleucel-T and control-diet, including objective response rate (partial + complete response), progression-free survival (PFS) and overall survival (OS), and changes in prostate-specific antigen (PSA).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a longitudinal randomized parallel groups design of n=30 subjects randomized in a 1:1 ratio to either sipuleucel-T plus control diet arm (20% protein content) or sipuleucel-T plus intervention low-protein content diet (10% protein diet).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Feasibility Study of Sipuleucel-T vs. Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC)
Actual Study Start Date : December 19, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Placebo Comparator: Control protein diet arm
20% protein content
Other: Control protein diet
Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).

Experimental: Low protein diet arm
10% protein content
Other: Low protein diet
Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).




Primary Outcome Measures :
  1. Adherence to diet intervention [ Time Frame: 6 weeks ]
    BUN and UUN laboratory values


Secondary Outcome Measures :
  1. Feasibility of diet intervention [ Time Frame: 6 weeks ]
    Patient self-report of compliance

  2. Feasibility of diet intervention [ Time Frame: 6 weeks ]
    Rate of drop-out

  3. Feasibility of diet intervention [ Time Frame: 6 weeks ]
    Rate of enrollment

  4. Safety and tolerability of diet intervention combined with sipuleucel-T treatment [ Time Frame: 6 weeks ]
    Rate of adverse events per CTCAE

  5. Rate of immune response [ Time Frame: 6, 12, and 14 weeks ]
    IFN-γ ELISpot specific for PA2024 laboratory values

  6. Progression free survival [ Time Frame: 2 years ]
    Length of time during and after the treatment that a patient lives with the disease but it does not get worse

  7. Overall survival [ Time Frame: 2 years ]
    Length of time start of treatment that patients are still alive



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   This study is for men with asymptomatic or minimally symptomatic, metastatic, androgen independent prostate cancer.
Accepts Healthy Volunteers:   No
Criteria

ELIGIBILITY CRITERIA Men at least 18 years of age with asymptomatic or minimally symptomatic, metastatic, androgen independent prostate cancer will be recruited for this study. Before the initiation of screening procedures, the patient will undergo the Informed Consent Process which includes signing an Institutional Review Board (IRB)-approved consent form. The subject will subsequently undergo screening assessments to determine if he meets the eligibility criteria for the study.

Inclusion Criteria

  • Histologically documented adenocarcinoma of the prostate.
  • Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan of the chest, abdomen, and pelvis
  • Androgen independent prostatic adenocarcinoma. Subjects must have current or historical evidence of disease progression concomitant with surgical or medical castration, as demonstrated by PSA progression OR progression of measurable disease OR progression of non-measurable disease as defined below:

    • PSA: Two consecutive PSA values, at least 14 days apart, each ≥ 5.0 ng/mL and ≥ 50% above the minimum PSA observed during castration therapy or above the pre-treatment value if there was no response.
    • Measurable disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The change will be measured against the best response to castration therapy or against the pre-castration measurements if there was no response.
    • Non-measurable disease: Soft tissue disease: The appearance of 1 or more new lesions, and/or unequivocal worsening of non-measurable disease when compared to imaging studies acquired during castration therapy or against the pre-castration studies if there was no response.
    • Bone disease: Appearance of 2 or more new areas of abnormal uptake on bone scan when compared to imaging studies acquired during castration therapy or against the pre-castration studies if there was no response. Increased uptake of pre-existing lesions on bone scan does not constitute progression.
    • Serum PSA ≥ 5.0 ng/mL
    • Castration levels of testosterone (< 50 ng/dL) achieved via medical or surgical castration. Surgical castration must have occurred at least 3 months prior to registration. Subjects who are not surgically castrate must be receiving medical castration therapy, have initiated such therapy at least 3 months prior to registration, and continue such therapy until the time of confirmed objective disease progression.
  • Life expectancy of at least 6 months
  • Men ≥ 18 years of age
  • Adequate hematologic, renal, and liver function as evidenced by the following:

    • White blood cell (WBC) ≥ 2,500 cells/μL
    • Absolute neutrophil count (ANC) ≥ 1,000 cells/μL
    • Platelet Count ≥ 100,000 cells/μL
    • Hemoglobin (HgB) ≥ 9.0 g/dL
    • Creatinine ≤ 2.0 mg/dL
    • Total bilirubin ≤ 2 x upper limit of normal (ULN)
    • Aspartate aminotransaminase (AST, SGOT) ≤ 2.5 x ULN
    • Alanine aminotransaminase (ALT, SGPT) ≤ 2.5 x ULN

Exclusion Criteria

  • The presence of lung, liver, or known brain metastases, malignant pleural effusions, or malignant ascites.
  • Moderate or severe symptomatic metastatic disease. Subjects who meet either of the following criteria must be excluded:

    • A requirement for treatment with opioid analgesics for any reason within 28 days prior to registration
    • Average weekly pain score of 4 or more as reported on the 10-point Visual Analog Scale (VAS) on the Registration Pain Log
  • Eastern Cooperative Oncology Group (ECOG) performance status > 2
  • Use of non-steroidal antiandrogens (e.g., flutamide, nilutamide, or bicalutamide) within 6 weeks of registration.
  • Treatment with chemotherapy within 28 days of registration including subjects who received more than 2 chemotherapy regimens in the metastatic setting at any time prior to registration.
  • Treatment with any of the following medications or interventions within 28 days of registration:

    • Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable.
    • Ketoconazole
    • High dose calcitriol [1,25(OH)2VitD] (i.e., > 7.0 μg/week)
    • Any other systemic therapy for prostate cancer (except for medical castration)
  • Prior treatment with sipuleucel-T (on clinical trial or as part of standard of care)
  • Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography > 50%) or spinal cord compression
  • Paget's disease of bone
  • A history of stage III or greater cancer, excluding prostate cancer. Basal or squamous cell skin cancers must have been adequately treated and the subject must be disease-free at the time of registration. Subjects with a history of stage I or II cancer must have been adequately treated and been disease-free for ≥ 3 years at the time of registration.
  • A requirement for systemic immunosuppressive therapy for any reason
  • Any infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5°F or 38.1°C) within 1 week prior to registration
  • A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging
  • Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03329742


Contacts
Layout table for location contacts
Contact: Marietta Moore, RN 317-274-7477 marlmoor@iupui.edu

Locations
Layout table for location information
United States, Indiana
Indiana University Hospital Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Marietta Moore, RN    317-274-7477    marlmoor@iu.edu   
Principal Investigator: Roberto Pili, MD         
Indiana University Melvin and Bren Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Marietta Moore, RN    317-274-7477    marlmoor@iu.edu   
Principal Investigator: Roberto Pili, MD         
Sponsors and Collaborators
Indiana University
Indiana University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Roberto Pili, MD Indiana University

Layout table for additonal information
Responsible Party: Roberto Pili, Professor, Indiana University
ClinicalTrials.gov Identifier: NCT03329742     History of Changes
Other Study ID Numbers: IUSCC-0614
1706081520 ( Other Identifier: Indiana University IRB )
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: September 12, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases